BIO 2026: Making biotech IPOs great again and the forgotten pharma antitrust review

SEC has rolled out new regulations (dubbed 'Make IPOs Great Again' or MIPOGA) to ease the path for biotech IPOs by simplifying disclosure and shortening filing timelines, while also loosening the first‑year public reporting burden for new biopharma companies.

Antitrust scrutiny of biotech IPOs and drugmakers is being eclipsed by drug‑pricing policy as the dominant regulatory concern, with attention shifting to the SEC and broader capital‑markets rules, not the DOJ or FTC.

The BIO 2026 coverage frames a broader market shift:
a surge of large, late‑stage biotech IPOs (e.g., Parabilis, Kailera) and a dense deal environment, even as the earlier emphasis on antitrust in pharma M&A fades into the background.